×

CATB – catabasis pharmaceuticals (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day CATB SPY QQQ SPX
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size


Shares at ask / bid


Off exchange

Top News Gainers
2/13 Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment 24.8%
9/28 Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society 20.5%
9/14 Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society 15.9%
4/17 Catabasis to cut workforce 42% in restructuring move; shares down 6% after hours [Seeking Alpha] 8.4%
10/4 Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018 6.3%
6/19 Form 8-K CATABASIS PHARMACEUTICAL For: Jun 19 5.6%
2/23 Form SC 13G CATABASIS PHARMACEUTICAL Filed by: Corriente Advisors, LLC 5.5%
10/3 Today's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals 5.2%
1/18 Catabasis Pharmaceuticals Inc (NASDAQ: CATB) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.1%
10/5 Catabasis Pharmaceuticals (CATB) Open-Label Extension Eesults from the MoveDMD Trial and the Phase 3 Clinical Trial Plan for Edasalonexent - Slideshow [Seeking Alpha] 4.0%

Don’t Miss Out On The Next BIG Stock Move